Feature | EuroPCR | May 10, 2019

EuroPCR 2019 Hot Line Late-Breaking Interventional Cardiology Trials

EuroPCR 2019 Hot Line Late Breaking trial presentations.

May 10, 2019 — Here is the list of the late-breaking hot line studies being presented at the 2019 EuroPCR interventional cardiology meeting, May 21-24, in Paris, France.

EuroPCR 2019 Hot Line and Trial Update
Tuesday May 21, 12:00 - 13:15, Main Arena, Level 1
   • Mitral regurgitation after MitraClip implantation: relationship between residual mitral regurgitation and clinical and functional outcomes from the COAPT trial. Presented by S. Kar.

   • Percutaneous edge-to-edge repair in patients with heart failure and secondary mitral regurgitation: a PCR statement. Presented by B. Prendergast.

   • GLOBAL Leaders substudy: ticagrelor monotherapy in complex PCI (multivessel, long lesions, bifurcation)
Presented by P.W. Serruys

   • Three-year clinical outcome following treatment with thin, very thin or ultrathin strut DES in small coronary vessels in BIO-RESORT. Presented by C. Von Birgelen

   • Real-life clinical outcomes with the use of an ultrathin sirolimus-eluting stent: a report from the Swedish coronary angiography and angioplasty registry. Presented by S. Buccheri.

 

Long-term Clinical Outcomes After TAVI
Tuesday May 21, 13:45 - 15:15 Theatre Bordeaux, Level 3

   • Five-year outcomes after TAVI with balloon-expandable vs. self-expanding valves: results from the CHOICE randomized clinical trial. Presented by M. Abdel-Wahab.

   • Valve performance and echocardiographic data throughout eight-year follow-up after TAVR. Presented by L. Testa.

   • 10-year follow-up of patients treated with TAVI. Presented by J. Sathananthan.

   • Prosthetic valve endocarditis after transcatheter or surgical AVR with a bioprosthesis. Presented by N. Moriyama.

   • Infective endocarditis after TAVI - A nationwide study. Presented by H. Bjursten.

   • Impact of Renin-Angiotensin System inhibition in patients following TAVI. The multicentre RASTAVI study. Presented by I.J. Amat-Santos.

 

Peripheral Interventions and Techniques for Access Site
Tuesday May 21, 13:45 -15:15, Room 342A, Level 3

   • Ultrasound guidance to reduce vascular complications of percutaneous transfemoral TAVR. Presented by F. Vincent.

   • Standard vs. Ultrasound-guided Radial and Femoral access (SURF) - A randomized controlled trial. Presented by P. Nguyen.

   • Echo-doppler evaluation of radial artery permeability following coronary angiography. Presented by A. Rougé.

   • Six-month clinical outcomes of sirolimus-eluting bioresorbable peripheral scaffold system indicated for below-the-knee lesions. Presented by V. Someshwar.

   • Are DCB safe? Not all DCBs are the same. New data: EFFPAC 2-year safety and efficacy. Presented by U. Teichgräber.

 

Clinical Outcomes After Interventions With Drug-coated Balloons
Tuesday May 21, 15:30 -17:00 Theatre Bordeaux, Level 3

   • PCR Statement - Clinical outcomes after interventions with DCB. Presented by A. Lansky.

   • Short-term clinical outcomes after treatment of de novo coronary lesions, in-stent restenosis and totally occluded stenotic portion using sirolimus-eluting balloon. Presented by S. Selvamani.

   • DCB vs. DES for the treatment of small coronary artery lesions: angiographic analysis from the randomised BASKET-SMALL 2 trial. Presented by R. Jeger.

   • Percutaneous treatment and outcomes of small-vessel coronary artery disease: a report from the Swedish Coronary Angiography and Angioplasty Registry. Presented by A. Silverio.

   • Revascularization with paclitaxel-coated balloon angioplasty vs. drug-eluting stenting in AMI: a prospective, randomized controlled trial. Presented by N. Vos.

   • Angiographic and OCT assessment of a new DCB for the treatment of in-stent restenosis. Presented by J.M. De La Torre Hernandez.

   • Clinical outcome of a novel sirolimus-coated balloon in patients with coronary artery disease. Presented by B. Cortese.

 

Tricuspid and Mitral Valve Repair
Tuesday May 21, 15:30 -17:00, Room 342A, Level 3

   • Early procedural outcomes from subjects treated with next-generation MitraClip (NTR/XTR) system: initial observations from the Global EXPAND study. Presented by J. Hausleiter.

   • GISE registry of transcatheter treatment of mitral valve regurgitation (GIOTTO): beginning analysis of one-year follow-up. Presented by F. Bedogni.

   • Mitraclip procedure as bridge therapy for heart transplantation: the "MitraBridge" international study. Presented by C. Godino.

   • Leaflet edge-to-edge treatment vs. direct annuloplasty in patients for functional mitral regurgitation. Presented by M. Weber.

   • The mitral valve repair clinical trial (MAVERIC) - First presentation of the two-year follow-up in 45 patients. Presented by S. Redwood.

   • Percutaneous edge-to-edge repair for tricuspid regurgitation: primary outcomes from the TRILUMINATE clinical trial. Presented by G. Nickenig.

 

Hotline: new developments in TAVI
Wednesday May 22, 8:30-10 a.m. Theatre Bordeaux, Level 3

   • TAVR with a supra-annular, self-expanding valve in patients at low risk of mortality following surgery. Presented by T. Modine.

   • 30-day outcomes following TAVI with a supra-annular self-expanding valve with pericardial wrap: primary results from the FORWARDPRO study. Presented by E. Grube.

   • Acute outcomes of a novel transcatheter heart valve to treat degenerated surgical valves - The VIVALL multicentre, single-arm, pilot study. Presented by U. Schaefer.

   • Safety, feasibility and acute performance of the Leaflex Performer when used pre-TAVI in aortic stenosis patients - The Leaflex Performer feasibility study. Presented by A. Baumbach.

   • One-year clinical outcomes of India's first indigenously designed and manufactured TAVR system. Presented by A. Seth.

   • Clinical outcomes of the Portico transcatheter aortic valve delivered via alternative access: 30-day results of the Portico ALT study. Presented by A. Linke.

 

Early trials and First-in-Man in mitral valve replacement
Wednesday May 22, 8:30-10 a.m. Room 342A, Level 3

   • Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation. Presented by V. Badhwar.

   • Transcatheter mitral valve implantation in patients with severe mitral annular calcification: early results from the Tendyne MAC study. Presented by M. Goessl.

   • One-year outcomes of transcatheter mitral valve-in-valve, valve-in-ring and valve-in-mitral annular calcification: results from the MITRAL trial. Presented by M. Guerrero.

   • Early feasibility study of the Cardiovalve transfemoral mitral valve system. Presented by F. Maisano.

   • Innovative design of a transcatheter transapical mitral valve and update on Tiara I and Tiara II clinical data. Presented by L. Conradi.

 

Innovative First-in-Man trials and early phase studies
Wednesday May 22, 10:30-12:00 Room 342A Level 3

   • Percutaneous therapeutic IVUS pulmonary artery denervation for the treatment of pulmonary arterial hypertension (TROPHY1): a multicentre, international, open-label trial. Presented by A. Rothman.

   • Comparison of radiofrequency ablation vs. cryodenervation in patients with pre-capillary pulmonary hypertension. Presented by D. Feschenko.

   • Validation of a novel catheter-based renal denervation system of cryoablation (Cryo-RDN) in patients with resistant hypertension: a first-in-man study. Presented by J.B. Ge.

   • Renal denervation prevents atrial fibrillation and reduce cardiovascular death in patients with hypertensive heart disease. Presented by M. Heradien.

   • NOGA-guided intramyocardial CERA injections. Presented by M.W. Bergmann.

   • Early transendocardial injection of autologous bone marrow-derived mononuclear cells following ischaemic myocardial events: the Alster-Helix registry. Presented by C. Paitazoglou.

   • The AFR-Prelieve trial: Atrial Flow Regulator in Heart Failure Patients. Presented by M.W. Bergmann.

 

Clinical outcomes after DES implantation: impact of strut thickness
Wednesday May 22, 10:30-12:00 Theatre Bordeaux, Level 3

   • Insight in real-world PCI practice and clinical outcomes of patients treated with a new-generation DES. Presented by M. Roffi.

   • Revascularisation strategy of multivessel PCI - Data from a worldwide registry. Presented by D. Hildick-Smith.

   • Target AC 2-year follow up results. Presented by B. Xu.

   • DESSOLVE III: a randomised comparison of a sirolimus-eluting bioabsorbable polymer-coated stent vs. an everolimus-eluting durable polymer stent in an all-comer population - 36-month update. Presented by P.W. Serruys.

   • Clinical outcomes with cobalt chromium biolimus-eluting compared with stainless steel biolimus-eluting DES in all-comer patients - Registry. Presented by I. Menown.

   • MILES-Global - Safety and efficacy of sirolimus-eluting stent system in all-comer real-world population with coronary artery stenosis. Presented by M. Hudec.

   • Nine-month clinical outcomes of a biodegradable polymer ultrathin sirolimus-eluting stent in an all-comer population undergoing PCI. Presented by I. Menown.

 

Trials and registries - Clinical outcomes after DES implantation for complex PCI
Wednesday May 22, 14:45 - 16:15 Theatre Bordeaux, Level 3

   • The CELTIC Bifurcation study. Presented by S. Walsh.

   • Reverse TAP vs. DK crush for coronary bifurcations: interim analysis of the rTAP trial. Presented by I. Tsiafoutis.

   • The impact of the extent of side branch disease on outcomes following bifurcation stenting. Presented by M. Zimarino.

   • A global clinical study of world's first sirolimus-eluting tapered coronary stent system for diffused long coronary lesions. Presented by P. Agostoni.

   • Safety and performance of the world's first tapered coronary stent for long coronary lesions: six-month experience in real world settings. Presented by D. Davidson.

   • CONventional antegrade vs. Sub-Intimal Synergy sTENTing in CTO. One-year OCT findings and two-year clinical outcomes. Presented by S. Walsh.

 

Managing bleeding risk in search of optimal drug-device synergy
Thursday May 23, 08:30-10:00 Theatre Bordeaux, Level 3

   • The risk of major bleeding with novel antiplatelet agents after an acute coronary event: a comparison of ticagrelor and clopidogrel in 5,116 consecutive patients in clinical practice. Presented by L. Mullen.

   • Microvascular integrity and left ventricular function recovery after clopidogrel or ticagrelor administration, in patients with STEMI treated with thrombolysis. Presented by M. Hamilos.

   • Randomized evaluation of short-term DAPT in patients with ACS treated with new-generation DES. Final two-year results of the REDUCE trial. Presented by G. De Luca.

   • Shorter duration of triple anti-thrombotic therapy in atrial fibrillation patients undergoing coronary stenting. Presented by T. Hoshi.

   • LAA occlusion with the Amplatzer Amulet device: primary results of the prospective global Amulet observational study. Presented by D. Hildick-Smith.

 

 

Long term clinical outcomes after Bioresorbable Stent (BRS) implantation
Thursday May 23, 10:30-12:00 Theatre Bordeaux, Level 3

   • Final three-year outcomes of patients receiving everolimus-eluting BRS in real-world practice: the ABSORB U.K. registry. Presented by N.E.J. West.

   • France ABSORB registry: three-year follow-up. Presented by R. Koning.

   • BRS implantation in STEMI patients: five-year follow-up of PRAGUE-19 study. Presented by P. Tousek.

   • Comparison of ABSORB BRS with Xience everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes of the AIDA trial. Presented by J. Wykrzykowska.

   • MeRes-1 Extend: Two-year clinical and imaging outcome results with a thin-strut, sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. Presented by A. Abizaid.

   • Three-year clinical and two-year multimodality imaging results of thin-strut sirolimus-eluting BRS in patients with coronary artery disease. Presented by P. Chandra.

 

 

TAVI Randomized Trials and Registries: Procedural Aspects and Outcomes

THURSDAY 23 MAY 2019 10:30 -12:00 ROOM 341 / LEVEL 3

   • Predilatation vs. direct TAVI: DIRECTAVI trial. Presented by F. Leclercq.

   • Comparison of pre-dilatation vs. direct implantation in TAVI with a self-expanding valve. A multicentre randomized trial. Presented by K. Toutouzas.

   • Clinical predictors for procedural stroke and implications for embolic protection device during TAVI: results from the multicentre Transcatheter Aortic valve implantation in-hoSpital stroKe study (TASK study). Presented by I.M. Barbash.

Bicuspid aortic valve morphology and outcomes after TAVR. Presented by R. Makkar.

   • Annular vs. supra-annular sizing for TAVR in bicuspid aortic valve stenosis. Presented by W.K. Kim.

   • TAVI-SMALL: international multicentre registry to evaluate performance of currently available self-expandable valves in small aortic annuli. Presented by D. Regazzoli.

   • ASSESS-REGURGE: quantitative assessment of aortic regurgitation using videodensitometry in a multicontinental trial. Presented by R. Modolo.

   • A randomized, sham-controlled study of forced diuresis with matched hydration in reducing acute kidney injury during TAVI (REDUCE-AKI). Presented by Y. Arbel.

 

New Trials in Coronary Imaging and Physiology
THURSDAY 23 MAY 2019 14:45 -16:15 THEATRE BORDEAUX / LEVEL 3

   • The use of an FFR-CT revascularization planning-tool to guide coronary artery disease management in patients with multivessel disease. Presented by E. Van Belle.

   • Redefining physiological patterns (diffuse versus focal) of epicardial disease by coronary pressure pullbacks. Presented by C. Collet.

   • A randomized trial evaluating on-line 3-D optical frequency domain imaging guided PCI vs. angiography guided in bifurcation lesions. Presented by Y. Onuma.

   • Optical coherence guidance for distal left main stenting - Final results of the ROCK II study. Presented by B. Cortese.

   • A serial optical frequency domain imaging study of early and late vascular responses of sirolimus-eluting stent with bioresorbable polymer for treatment of STEMI and stable angina pectoris patients - Final results of MECHANISM-ULTIMASTER. Presented by Y. Morino.

   • Accuracy of OCT-based FFR in identifying hemodynamic significance of coronary stenosis. Presented by S. Tu.

   • Prognostic value of quantitative flow ratio measured immediately after successful stent implantation: the international multicentre prospective HAWKEYE study. Presented by S. Biscaglia.

   • Routine FFR measurement after PCI: two-year follow-up of the the FFR-search study. Presented by R. Diletti.

 

Stents and Procedural Techniques for the Treatment of High-risk Patients
THURSDAY 23 MAY 2019 16:30 -18:00 THEATRE BORDEAUX / LEVEL 3

   • Results of the prospective European Registry on Rotational Atherectomy Presented by D. Carrié

   • OCT assessment of calcium severity in patients treated with rotational atherectomy vs. modified balloons prior to DES implantation: results from the randomized PREPARE-CALC trial. Presented by M. Abdel-Wahab.

   • Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI scoring study.  Presented by F. Alfonso Manterola.

   • Everolimus-eluting BRS system in the treatment of cardiac allograft vasculopathy: the Cardiac Allograft Reparative Therapy (CART) prospective multicentre pilot study. Presented by F. Ribichini.

   • Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: A randomized trial. Presented by C. den Uil.

   • Observational multicentre registry of patient treated with IMPella mechanical circulatory support device in ITaly: the IMP-IT registry. Presented by A. Chieffo.

   • Cardiac arrest and death during elective PCI: a European multicentre registry. Presented by K. Ameloot.

For more information on the conference: www.pcronline.com

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init